Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Toxicologic Pathology|October 8, 2010
Use of tissue cross-reactivity studies in the development of antibody-based biopharmaceuticals: history, experience, methodology, and future directionsMichael W Leach, Wendy G Halpern, Carol W Johnson, et al.
Regulatory Toxicology and Pharmacology : RTP|January 24, 2021
Classic and evolving approaches to evaluating cross reactivity of mAb and mAb-like molecules - A survey of industry 2008-2019Timothy K MacLachlan, Shari Price, Joy Cavagnaro, et al.
Advances in Therapy|September 3, 2016
Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade® (Infliximab)Mazin Derzi, Theodore R Johnson, Ahmed M Shoieb, et al.
Journal of Toxicologic Pathology|March 15, 2016
Nonproliferative and Proliferative Lesions of the Gastrointestinal Tract, Pancreas and Salivary Glands of the Rat and MouseThomas Nolte, Patricia Brander-Weber, Charles Dangler, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 13, 2011
Cytosolic phospholipase A2α blockade abrogates disease during the tissue-damage effector phase of experimental autoimmune encephalomyelitis by its action on APCsParesh Thakker, Suzana Marusic, Nancy L Stedman, et al.
Mabs|February 9, 2016
Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challengesKathryn Chapman, Akosua Adjei, Paul Baldrick, et al.
Clinical Pharmacology and Therapeutics|August 7, 2020
Strategies and Recommendations for Using a Data-Driven and Risk-Based Approach in the Selection of First-in-Human Starting Dose: An International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) AssessmentMichael W Leach, David O Clarke, Sherri Dudal, et al.
The Journal of Experimental Medicine|September 21, 2005
Cytosolic phospholipase A2 alpha-deficient mice are resistant to experimental autoimmune encephalomyelitisSuzana Marusic, Michael W Leach, Jeffrey W Pelker, et al.
Toxicologic Pathology|March 8, 2014
Comparative nonclinical assessments of the proposed biosimilar PF-05280586 and rituximab (MabThera®)Anne M Ryan, Sharon A Sokolowski, Chee-Keng Ng, et al.
Journal of Neuroimmunology|October 3, 2008
Blockade of cytosolic phospholipase A2 alpha prevents experimental autoimmune encephalomyelitis and diminishes development of Th1 and Th17 responsesSuzana Marusic, Paresh Thakker, Jeffrey W Pelker, et al.
Pageof 4